# US 2022/0025045 A1 · Compounds and methods for treatment of head and neck cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025045 A1
- Document ID: US20220025045A1
- Status: Published application
- Kind: A1
- Application number: 17/418,271
- Filed: 2019-12-20
- Published: 2022-01-27
- Earliest claimed: 2018-12-26
- Assignees: Innate Pharma
- Applicants: Innate Pharma
- Inventors: OLIVIER BENAC; STÉPHANIE CHANTEUX; IVAN PERROT; BENJAMIN ROSSI; NICOLAS VIAUD
- Web page: https://patentgrep.com/patent/US20220025045A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of treating an individual who has a head and neck squamous cell carcinoma (HNSCC), the method comprising administering to the individual an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2 in combination with cetuximab.

### Claim 32 (depends on 31)

The method of claim 31, wherein the antibody that binds a human ILT-2 polypeptide lacks an Fc domain or has a human Fc domain that is modified to reduce binding between the Fc domain and an Fcγ receptor.

### Claim 33 (depends on 31)

The method of claim 31, wherein the antibody that binds a human ILT-2 polypeptide does not inhibit the binding of a soluble human ILT-6 protein to a HLA class I molecule.

### Claim 34 (depends on 31)

The method of claim 31, wherein the individual has a HLA-G and/or HLA-A2 negative cancer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the treatment does not require a prior step of determining whether the individual has a HLA-G and/or HLA-A2 positive cancer.

### Claim 36 (depends on 31)

The method of claim 31, wherein the antibody that binds a human ILT-2 polypeptide competes for binding to an ILT2 polypeptide of SEQ ID NO: 1 with an antibody comprising the heavy and light chain CDRs, or the heavy and light chain variable regions, of antibody 12D12, 3H5, 27H5, 26D8, 27C10 or 18E1.

### Claim 37 (depends on 31)

The method of claim 31, wherein the antibody that binds a human ILT-2 polypeptide comprises a modified human IgG1 Fc domain comprising N-linked glycosylation at Kabat residue N297 and comprising an amino acid substitution at Kabat residue(s) 234 and 235, optionally further at Kabat residue 331, optionally at Kabat residues 234, 235, 237 and at Kabat residues 330 and/or 331, optionally wherein the Fc domain comprises L234A/L235E/P331S substitutions, L234F/L235E/P331S substitutions, L234A/L235E/G237A/P331S substitutions, or L234A/L235E/G237A/A330S/P331S substitutions.

### Claim 38 (depends on 31)

The method of claim 31, wherein said antibody that binds ILT-2 is capable of enhancing the cytotoxicity of NK cells in a 4-hour in vitro 51Cr release cytotoxicity assay in which NK cells that express ILT2 are purified from human donors and incubated with target cells that express at their surface HLA-G polypeptides.

### Claim 39 (depends on 31)

The method of claim 31, wherein the antibody that binds a human ILT-2 polypeptide does not inhibit the binding of a soluble human ILT-6 protein to a HLA class I molecule.

### Claim 40 (depends on 31)

The method of claim 31, wherein the antibody has reduced binding to (i) a mutant ILT2 polypeptide comprising the mutations E34A, R36A, Y76I, A82S, R84L (with reference to SEQ ID NO: 2), (ii) a mutant ILT2 polypeptide comprising the mutations G29S, Q30L, Q33A, T32A, D80H (with reference to SEQ ID NO: 2), (iii) a mutant ILT2 polypeptide comprising the mutations F299I, Y300R, D301A, W328G, Q378A, K381N (with reference to SEQ ID NO: 2), or (iv) a mutant ILT2 polypeptide comprising the mutations W328G, Q330H, R347A, T349A, Y350S, Y355A (with reference to SEQ ID NO: 2), in each case relative to binding between the antibody and a wild-type ILT2 polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 41 (depends on 31)

The method of claim 31, wherein the antibody that binds ILT-2 comprises the heavy and light chain CDR1, 2 and 3 of antibody 12D12, 26D8, 18E1, 2A8A, 2A9, 2C4, 2C8, 2D8, 2E2B, 2E2C, 2E8, 2E11, 2H2A, 2H12, 1A10D, 1E4B, 3E5, 3E7A, 3E7B, 3E9B, 4C11B, 4E3A, 4E3B, 4H3, 5D9, 6C6, 2H2B, 48F12, 3F5, 12D12, 3H5, 27H5, 26D8, 27C10 or 18E1.

### Claim 42 (depends on 31)

The method of claim 31, wherein the antibody that binds ILT-2 and the antibody that binds EGFR are formulated for separate administration and are administered concurrently or sequentially.

### Claim 43

A method of treating an individual who has an HNSCC, the method comprising administering to the individual an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2 in combination with cetuximab, wherein the treatment is further in combination with an antibody that neutralizes the inhibitory activity of PD-1.

### Claim 44

A pharmaceutical composition comprising an antibody that binds ILT-2 and an antibody that binds EGFR, wherein the antibody that binds ILT-2 has an Fc domain that is modified to reduce binding between the Fc domain and an Fcγ receptor.

### Claim 45

A kit comprising a pharmaceutical composition containing an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2, and a second pharmaceutical composition containing an anti-EGFR antibody, and instructions to administer said anti-EGFR antibody with an anti-ILT-2 antibody.
